European approval is based on robust Phase III data showing Cosentyx provided rapid symptom relief from as early as Week 4, with response rates continuing to improve up to 1 year1,3-5
The latest extension of Masimo and Philips’ ongoing collaboration will help enable clinicians to make quick and informed decisions without the need for additional monitoring equipment
Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder
SCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royalties
Women of all ages will get round-the-clock access to comprehensive treatment
Patients will no longer need to travel abroad for treatment of acute cardiac diseases
New workflow integrates the xCELLigence RTCA HT with the BioTek BioSpa 8 Automated Incubator
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
The new facility will be able to handle four times as many patients as the previous facility.
Subscribe To Our Newsletter & Stay Updated
